A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
Study sponsor: Lipocine Inc. · LPCN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-03-01Actual
Enrollment · participants25Actual
Source updated2024-07-17Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.